Boston Scientific Corporation
As of Fiscal Year 2025 (ended December 31, 2025)
Key KPIs at a Glance
| Metric | Value |
|---|---|
| Total Net Sales (FY2025) | $20.07 billion, up 19.9% year-over-year reported (15.8% organic) |
| Net Income (FY2025, GAAP) | $2.90 billion, up 56% year-over-year (vs. $1.85 billion in FY2024) |
| Diluted EPS (FY2025, GAAP) | $1.94, up from $1.25 in FY2024 |
| Operating Income (FY2025) | $3.61 billion, an 18.0% operating margin (vs. 15.6% in FY2024) |
| Gross Margin (FY2025) | 69.0% of net sales (vs. 68.7% in FY2024) |
| Net Margin (FY2025) | 14.4% of net sales (vs. 11.1% in FY2024) |
| R&D Spending (FY2025) | $2.05 billion, 10.2% of net sales, up from $1.62 billion in FY2024 |
| SG&A Spending (FY2025) | $6.89 billion, 34.3% of net sales |
| Employees Worldwide | Approximately 59,000 as of Dec. 31, 2025, with about 60% located outside the U.S. (per FY2025 Form 10-K) |
| Cardiovascular Segment (FY2025) | $13.25 billion in net sales, up 23.2% reported / 20.8% organic year-over-year |
| MedSurg Segment (FY2025) | $6.82 billion in net sales, up 13.9% reported / 6.7% organic year-over-year |
| Emerging Markets Net Sales (FY2025) | $2.99 billion, up 11.4% year-over-year (overlaps with other regional categories above) |
| Watchman / LAA Closure Market Position (third-party estimate) | Boston Scientific's Watchman held an estimated ~94% share of the implanted left atrial appendage closure device market, per GlobalData analyst Joselia Carlos (July 2023 estimate, based on 2022 data) — dated, and likely narrower now given Abbott's Amulet competition |
| FY2026 Guidance (issued Feb 4, 2026) | Reported net sales growth of 10.5%-11.5%; organic growth of 10.0%-11.0%; adjusted diluted EPS of $3.43-$3.49 |
Sources: All figures are company-disclosed GAAP results from Boston Scientific Corporation's Q4/FY2025 earnings release (8-K/press release dated Feb 4, 2026, news.bostonscientific.com and sec.gov/Archives/edgar/data/885725/000088572526000006/q42025earningsrelease.htm) and its FY2025 Form 10-K filed Feb 17, 2026 (sec.gov), unless noted otherwise. Revenue-by-segment pie: Cardiovascular ($13,250M) plus the three MedSurg product categories Endoscopy ($2,916M), Urology ($2,709M) and Neuromodulation ($1,199M) sum to exactly $20,074M, matching total FY2025 net sales; Boston Scientific does not publicly disclose a further breakdown of the Cardiovascular segment (e.g., Interventional Cardiology/Watchman/Electrophysiology) by dollar revenue, nor does it disclose operating income by segment, so no segment-level profitability widget is included. Revenue-by-geography pie uses the company's reported regional lines (US, EMEA, APAC, LACA); these sum to $20,073M, $1M below the $20,074M total due to rounding of each regional figure to the nearest million as reported by the company. The company's separately reported 'Emerging Markets' net sales ($2,985M) is a cross-cutting overlay of the other regions (not additive) and is therefore omitted from the geography pie and shown only in the KPI table. The market-share figure for Boston Scientific's left atrial appendage closure (Watchman) business is a third-party estimate from GlobalData analyst Joselia Carlos (published via Medical Product Outsourcing, July 5, 2023, citing Boston Scientific's 2022 annual report), not a company disclosure; it is dated and may not reflect 2025 competitive dynamics (e.g., Abbott's Amplatzer Amulet share gains), so it is flagged as an estimate with its original date. FY2026 revenue/EPS figures are forward-looking company guidance issued with the Feb 4, 2026 release, not actuals. 5-year revenue series (2021-2025) compiled from Boston Scientific's FY2021-FY2025 earnings releases.